This could imply altered intracellular and paracrine signalling from tumor cells in response to alternative NF-κB activation, since RelA-P50 and RelB–P100/P52 complexes bind to NF-κB binding sites of different promoters [41]. The gene discussed is NFKB2; the disease is neoplasm.